The Heart Drug That Just Rewrote the Rules for Sick Teenagers

Beyond the headline number, secondary measures improved too: resting obstruction went down, the heart's ability to relax between beats got better, and wall thickness decreased. The drug wasn't just easing symptoms; it was addressing the underlying mechanical problem.

The Safety Question Parents Actually Care About

When you're talking about putting a teenager on a cardiac drug, safety isn't a footnote. It's the whole conversation. Camzyos carries a known risk in adults: if it works too well, it can weaken the heart's pumping function to dangerous levels. That's why it comes with a REMS program (a special FDA-mandated monitoring system) requiring regular echocardiograms to check heart function.

So how did the adolescents fare? Reassuringly well. No patients in SCOUT-HCM had their heart's ejection fraction drop below 50%, which is the threshold where doctors start worrying. No adverse events led to anyone stopping the drug. And the overall safety profile matched what's been seen in adults, with no new red flags.

That said, the monitoring requirements aren't going away. Every patient still needs echocardiograms before and during treatment. For pediatric cardiologists, that's a reasonable trade-off when the alternative is borrowing from the adult medicine cabinet and hoping for the best.

Why Pediatric Cardiologists Are Calling This a "Massive Unmet Need"

Hypertrophic cardiomyopathy in kids is rare, affecting roughly 3 per 100,000 children. About 24% of pediatric HCM patients have the obstructive form, and around 29% of pediatric oHCM patients are symptomatic. We're talking about a small but very real population of young people whose hearts are working against them.

The label specifically covers patients weighing at least 30 kg (about 66 pounds), which practically means most adolescents 12 and up. Joseph Rossano, MD, described the approval as introducing a disease-targeted treatment option for this group. Coverage from HCPLive framed it as addressing a "massive unmet need."

The distinction matters. Beta-blockers and calcium channel blockers treat symptoms. Camzyos targets the underlying problem: the overactive contraction of thickened heart muscle that causes the obstruction in the first place. It's the difference between turning down the volume on a fire alarm and actually putting out the fire.

The Business Side: A Billion-Dollar Drug Gets Bigger

For Bristol Myers Squibb, this isn't just a feel-good story. Camzyos is already a commercial juggernaut, generating over $1 billion in sales in 2025. By the time of the pediatric label expansion, more than 25,000 U.S. patients were on the drug, prescribed by over 5,000 healthcare providers.

The pediatric indication won't double revenue overnight; the patient population is small. But it does two important things strategically. First, it broadens the addressable market into a population with zero approved alternatives. Second, it strengthens Camzyos's clinical story at a time when BMS needs differentiation.

That's because the cardiac myosin inhibitor market is no longer a one-horse race. Aficamten, a competing drug in the same class, is pressuring BMS to defend its territory. Having the only pediatric data and label in the category gives Camzyos a clinical moat that's hard to replicate quickly. Pediatric trials take years to design, enroll, and complete. BMS did the work, and now it has a head start that competitors can't shortcut.

What This Really Means

Zoom out for a second. In pediatric cardiology, approved therapies are vanishingly rare. Kids with oHCM have been managed with drugs designed for adults, procedures designed for adults, and evidence generated in adults. SCOUT-HCM was a 44-patient trial, which sounds tiny until you remember that enrolling even that many adolescents with a rare cardiac condition is a logistical feat.

The approval doesn't solve everything. The REMS monitoring requirements add complexity for families and clinics. Long-term pediatric safety data will take years to accumulate. And not every adolescent with HCM has the obstructive subtype that Camzyos targets.

But for the teenagers who do, the ones getting lightheaded on the basketball court or skipping activities because their hearts can't keep up, there's now an FDA-approved drug that goes after the root cause of their problem. That's not incremental progress. That's a first.

Amgen's $28 Billion Bet on Horizon Just Got a Whole Lot Smarter

Amgen's $27.8 billion Horizon Therapeutics acquisition just delivered its biggest pipeline surprise yet. A fusion protein that blocks immune cell crosstalk passed its first pivotal trial in Sjögren's disease, a condition with zero approved treatments, and the implications for Amgen's autoimmune franchise are massive.